Lymphogranuloma Venereum (LGV)

Overview

Lymphogranuloma venereum (LGV) is a sexually transmitted infection (STI) caused by certain serovars (L1, L2, and L3) of the bacterium Chlamydia trachomatis. Unlike the more common genital chlamydia infections (serovars D–K), LGV is characterized by a more aggressive invasion of the lymphatic system, leading to painful swollen lymph nodes (lymphadenitis) and, if untreated, chronic tissue damage.

Who it affects: LGV is most prevalent among men who have sex with men (MSM), particularly those who have sex with multiple partners or engage in receptive anal intercourse. Outbreaks have also been reported in heterosexual populations, especially in regions with limited STI screening resources.

Prevalence: Worldwide, LGV is considered a relatively rare STI, but incidence is rising in high‑income countries. In the United States, the CDC estimated ≈6,000 new cases per year, with >80 % occurring in MSM. In Europe, surveillance data from 2019 reported approximately 3,000 cases, mainly in the United Kingdom, France, and the Netherlands [CDC 2022; ECDC 2020]. In parts of sub‑Saharan Africa and Southeast Asia, LGV may be under‑diagnosed due to limited laboratory capacity.

Symptoms

LGV progresses through three classic stages, but many patients present with overlapping features. Symptoms vary by sex, site of infection, and stage.

Primary stage (1–4 weeks after exposure)

• Painless ulcer or papule at the site of inoculation (genital, anal, or oral). The lesion is often overlooked because it is small (<5 mm) and may heal spontaneously within 3–7 days.
• Occasional mucopurulent discharge if the ulcer erodes.

Secondary stage (2–6 weeks after primary lesion)

• painful, tender lymphadenopathy – often unilateral inguinal or femoral nodes that may coalesce into a “buboe” (fluctuant mass).
• Node may become fluctuant and drain pus, forming a sinus tract (known as “groove sign” when a line of tissue separates two enlarged nodes).
• Fever, malaise, night sweats and weight loss in some patients.
• In MSM with anal infection: rectal pain, tenesmus, mucous or bloody discharge, and constipation.

Tertiary (chronic) stage (months to years)

• Development of proctocolitis (inflammation of the rectum and colon) leading to strictures, fistulas, or ulcerations.
• Genital or anal elephantiasis – thickened, hypertrophic tissue due to chronic lymphatic obstruction.
• Persistent skin plaques or nodules that may be mistaken for other dermatologic conditions.

Because the primary lesion is often unnoticed, many patients first seek care for the painful swollen lymph nodes or rectal symptoms.

Causes and Risk Factors

Cause

LGV is caused by infection with C. trachomatis serovars L1, L2, or L3. The bacteria enter through microabrasions in mucosal surfaces and travel via lymphatic channels to regional nodes, provoking an intense inflammatory response.

Risk Factors

• Sexual behavior: unprotected anal or vaginal intercourse, especially with multiple partners.
• Men who have sex with men (MSM): highest risk group; co‑infection with HIV or other STIs increases susceptibility.
• Receptive anal intercourse: direct exposure of rectal mucosa to infected secretions.
• History of other STIs: prior chlamydia, gonorrhea, syphilis, or herpes simplex virus.
• Immune suppression: HIV infection, organ transplantation, or chronic corticosteroid use.
• Travel to endemic areas: parts of Africa, Asia, and the Caribbean where LGV is more common.

Diagnosis

Accurate diagnosis relies on a combination of clinical suspicion, laboratory testing, and, when needed, imaging.

Clinical evaluation

• Detailed sexual history (partners, condom use, recent travel).
• Physical exam focusing on genital, anal, and inguinal regions.

Laboratory tests

1. Nucleic acid amplification tests (NAATs): The gold standard. Samples can be taken from the ulcer, rectal swab, or lymph node aspirate. NAATs detect C. trachomatis DNA and can differentiate LGV serovars when using specialized assays.
2. PCR with genotype‑specific primers: Allows definitive identification of L1‑L3.
3. Serology: Not routinely used for acute diagnosis but may show rising IgG titres in chronic disease.

Imaging (if complications suspected)

• Ultrasound of inguinal nodes – helps differentiate abscess from solid lymphadenitis.
• Pelvic MRI or CT scan – for assessing rectal strictures, fistulas, or deep pelvic disease.

Differential diagnosis

Other conditions that can mimic LGV include chancroid, syphilis, herpes simplex, granuloma inguinale, and bacterial lymphadenitis. Laboratory confirmation is essential to avoid mismanagement.

Treatment Options

Prompt antibiotic therapy cures LGV and prevents long‑term complications. Treatment is recommended for both the patient and sexual partners.

First‑line antibiotics

• Doxycycline 100 mg orally twice daily for 21 days – the CDC’s preferred regimen [CDC 2021].
• Alternative for doxycycline‑contraindicated patients:
  • Erythromycin 500 mg orally four times daily for 21 days, or
  • Azithromycin 1 g orally once weekly for 3 doses (less evidence, used when adherence is a concern).

Management of complications

• Abscess drainage: Incision and drainage of fluctuant lymph nodes to relieve pain and prevent spread.
• Surgical intervention: For severe strictures, fistulas, or elephantiasis—may require bowel resection or reconstructive surgery.
• Adjunctive therapy: Pain control with NSAIDs, and stool softeners for proctitis.

Partner treatment and follow‑up

• All sexual partners within the previous 60 days should receive empiric treatment, regardless of symptoms.
• Repeat NAAT testing is recommended 3 months after therapy to confirm eradication, especially in HIV‑positive individuals.

Living with Lymphogranuloma Venereum

While LGV is curable, patients may need ongoing care to manage residual symptoms or prevent recurrence.

Daily management tips

• Medication adherence: Use alarms or pill organizers to complete the 21‑day doxycycline course.
• Hygiene: Keep the affected area clean and dry; apply warm compresses to reduce lymph node swelling.
• Dietary measures: High‑fiber diet and adequate hydration help prevent constipation and reduce strain on inflamed rectal tissue.
• Sexual health: Abstain from sexual activity until treatment is complete and symptoms have resolved; use condoms consistently thereafter.
• Psychosocial support: Consider counseling or support groups, as STI diagnoses can cause anxiety or stigma.

Monitoring

Schedule a follow‑up visit 2–4 weeks after completing antibiotics to assess symptom resolution and, if indicated, repeat NAAT testing. Persistent lymphadenopathy may warrant imaging or surgical consultation.

Prevention

• Consistent condom use during all types of sexual activity, especially anal intercourse.
• Regular STI screening for sexually active MSM and persons with multiple partners (at least annually, or more frequently if high risk).
• Pre‑exposure prophylaxis (PrEP) programs for HIV often include routine LGV testing as part of comprehensive care.
• Limit number of sexual partners and practice mutual monogamy when possible.
• Vaccination: No vaccine exists for LGV, but hepatitis A, B, and HPV vaccines protect against other sexually transmitted infections.
• Education: Community outreach targeting MSM and travelers to endemic regions improves early detection.

Complications

If left untreated, LGV can cause serious, sometimes irreversible damage.

• Chronic proctocolitis: leads to rectal strictures, fistulas, or bleeding.
• Lymphatic obstruction: resulting in genital or perianal elephantiasis.
• Infertility: scarring of the fallopian tubes in women (rare, as LGV is less common in females).
• Systemic spread: Rarely, bacteria can disseminate causing bacteremia or sepsis.
• Increased HIV transmission risk: Ulcerative lesions facilitate viral entry.

When to Seek Emergency Care

Key Take‑aways

Lymphogranuloma venereum is a curable STI caused by specific chlamydia serovars. Early recognition—especially among MSM and individuals with recent high‑risk sexual activity—is essential to prevent painful lymphadenitis, chronic proctocolitis, and other complications. A 21‑day doxycycline regimen, partner treatment, and consistent condom use are the cornerstones of management and prevention.

References: CDC. Sexually Transmitted Diseases Treatment Guidelines, 2021. link; ECDC. European Surveillance of STIs 2019; WHO. Sexually transmitted infections fact sheet; Mayo Clinic. LGV overview; Cleveland Clinic. Chlamydia infections.